Z Squared Inc.
Coeptis Therapeutics Holdings, Inc. (Nasdaq Capital Market: ticker symbol not specified in document) operates as a biopharmaceutical and technology company focused on developing innovative cell therapy platforms and advanced operational technologies. The company's website is https://coeptistx.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Z Squared Inc. does
In the company’s own words
Coeptis Therapeutics Holdings, Inc. (Nasdaq Capital Market: ticker symbol not specified in document) operates as a biopharmaceutical and technology company focused on developing innovative cell therapy platforms and advanced operational technologies. The company's website is https://coeptistx.com.
The company operates through two primary divisions. The biopharmaceutical division develops cell therapy platforms targeting cancer, autoimmune, and infectious diseases. Key programs include CD38-GEAR-NK, an autologous gene-edited natural killer cell therapeutic designed to protect CD38-positive NK cells from destruction by anti-CD38 monoclonal antibodies, with initial focus on multiple myeloma treatment. The company also develops CD38-Diagnostic, an in vitro diagnostic tool to identify cancer patients appropriate for anti-CD38 monoclonal antibody therapy. The SNAP-CAR platform represents a universal chimeric antigen receptor technology co-administered with antibody adaptors, with applications in both hematologic malignancies and solid tumors. Additionally, Coeptis holds interests in unmodified natural killer cell therapies for acute myeloid leukemia and acute respiratory diseases through licensing arrangements with Deverra Therapeutics.
The technology division, established through the December 2024 acquisition of NexGenAI Affiliates Network Platform, provides AI-powered marketing software and robotic process automation capabilities. The division offers managed digital marketing services including lead generation, content marketing, social media marketing, email marketing, account-based marketing, and marketing analytics.
Coeptis maintains majority ownership stakes in SNAP Biosciences, Inc. and GEAR Therapeutics, Inc., while wholly owning Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., and Coeptis Pharmaceuticals, LLC. The company currently employs six individuals, comprising four full-time and two part-time employees. The company was formed through a reverse merger in October 2022 when Bull Horn Holdings Corp. acquired Coeptis Therapeutics, Inc. In April 2025, Coeptis entered into a merger agreement with Z Squared, Inc., with expected closing in the second quarter of 2026, involving a spin-out of biotechnology operations.
Company details
- Sector
- Financials
- Industry
- Finance Services
- Headquarters
- FORT LAUDERDALE, FL
- Fiscal year end
- December
- CIK
- 1759186
- SIC
- 6199
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Z Squared Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Z Squared Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Z Squared Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Z Squared Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Z Squared Inc.'s last four quarterly filings that the numbers alone won't show?”